Ovid Therapeutics (OVID) Cash from Investing Activities Growth (3y) (2019 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Cash from Investing Activities Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -47.89% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 27.70% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | -39.73% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | -91.04% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -84.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -84.91% |
| Mar 31, 2026 | -41.83% |
| Dec 31, 2025 | -158.55% |
| Sep 30, 2025 | 66.04% |
| Jun 30, 2025 | 29.05% |
| Mar 31, 2025 | 88.90% |
| Dec 31, 2024 | 411.04% |
| Sep 30, 2024 | 87.20% |
| Jun 30, 2024 | 116.13% |
| Mar 31, 2024 | 1,106.30% |
| Dec 31, 2023 | -712.41% |
| Sep 30, 2023 | -384.63% |
| Jun 30, 2023 | -13.44% |
| Mar 31, 2023 | 99.00% |
| Dec 31, 2022 | 50.80% |
| Sep 30, 2022 | -372.52% |
| Jun 30, 2022 | -162.80% |
| Mar 31, 2022 | -393.13% |
| Dec 31, 2021 | -26.19% |
| Sep 30, 2021 | -26.07% |